We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
One Big Beautiful Bill Act: A Boon or Bane for Centene?
Read MoreHide Full Article
Key Takeaways
CNC may benefit from billing standardization but faces pressure from $1T in Medicaid cuts.
The bill could raise costs via eligibility checks and hurt ACA plan enrollment where CNC holds 23% share.
CNC's scale, IT investments and private market push may help offset losses and boost long-term resilience.
Centene Corporation (CNC - Free Report) , a major player in government-sponsored healthcare — including Medicaid, Medicare Advantage, and ACA marketplace plans — faces both opportunities and challenges under the One Big Beautiful Bill Act (OBBBA). Enacted in July 2025, this sweeping healthcare reform aims to simplify and digitize the U.S. healthcare payment system by consolidating medical billing and reducing administrative inefficiencies.
However, the bill also introduces significant cost-containment measures. Notably, it includes approximately $1 trillion in federal Medicaid cuts over the next decade and mandates eligibility verification every six months, which could raise administrative costs. Additionally, reductions in ACA subsidies may depress enrollment in individual marketplace plans—a key area where Centene holds a leading market share, about 23%.
Despite these headwinds, Centene stands to gain from the bill’s emphasis on billing standardization and digital infrastructure. With its scale and disciplined cost management, the company is well-positioned to enhance claims accuracy, reduce denials and improve cash flow. That said, transitioning to a unified billing system may involve substantial near-term investments in IT systems and compliance. Stricter billing regulations and standardized reimbursement rates could also put pressure on margins.
Nevertheless, Centene’s nationwide presence and deep experience navigating complex regulations provide it with a competitive edge. The new regulatory landscape also presents opportunities for Centene to develop tailored individual products and expand into private markets to offset potential Medicaid revenue losses. If the company manages this transition effectively, it could emerge leaner, more resilient and well-adapted to the evolving healthcare environment.
How Are Other Government Sponsored Health Plan Providers Placed?
Molina Healthcare (MOH - Free Report) , with nearly 88% Medicaid membership, faces major revenue challenges under OBBBA. Molina could be hit by tighter eligibility and shrinking enrollment. Still, Molina’s strong cost discipline and coordinated care model may support resilience amid the shifting healthcare policy environment.
UnitedHealth Group (UNH - Free Report) , with substantial Medicaid exposure, could also face revenue challenges due to OBBBA, given tighter eligibility and reduced enrollment. While UnitedHealth's diversified portfolio offers some protection, it must proactively respond to regulatory changes to safeguard its position in the government-sponsored healthcare market.
CNC’s Price Performance
Shares of CNC have lost 57.6% year to date, underperforming the industry.
Image Source: Zacks Investment Research
CNC’s Expensive Valuation
CNC trades at a forward 12-month price-to-earnings of 8.98, below the industry average of 11.96.
Image Source: Zacks Investment Research
Estimate Movements for CNC
The Zacks Consensus Estimate for CNC’s second-quarter and third-quarter 2025 EPS witnessed a southward revision over the past seven days. The consensus estimate for full-year 2025 and 2026 EPS also followed suit.
Image Source: Zacks Investment Research
The consensus estimate for CNC’s 2025 revenues indicates a year-over-year increase but the same for EPS suggests a decline. For 2026, the case is exactly the opposite.
CNC stock currently carries a Zacks Rank #5 (Strong Sell).
Image: Shutterstock
One Big Beautiful Bill Act: A Boon or Bane for Centene?
Key Takeaways
Centene Corporation (CNC - Free Report) , a major player in government-sponsored healthcare — including Medicaid, Medicare Advantage, and ACA marketplace plans — faces both opportunities and challenges under the One Big Beautiful Bill Act (OBBBA). Enacted in July 2025, this sweeping healthcare reform aims to simplify and digitize the U.S. healthcare payment system by consolidating medical billing and reducing administrative inefficiencies.
However, the bill also introduces significant cost-containment measures. Notably, it includes approximately $1 trillion in federal Medicaid cuts over the next decade and mandates eligibility verification every six months, which could raise administrative costs. Additionally, reductions in ACA subsidies may depress enrollment in individual marketplace plans—a key area where Centene holds a leading market share, about 23%.
Despite these headwinds, Centene stands to gain from the bill’s emphasis on billing standardization and digital infrastructure. With its scale and disciplined cost management, the company is well-positioned to enhance claims accuracy, reduce denials and improve cash flow. That said, transitioning to a unified billing system may involve substantial near-term investments in IT systems and compliance. Stricter billing regulations and standardized reimbursement rates could also put pressure on margins.
Nevertheless, Centene’s nationwide presence and deep experience navigating complex regulations provide it with a competitive edge. The new regulatory landscape also presents opportunities for Centene to develop tailored individual products and expand into private markets to offset potential Medicaid revenue losses. If the company manages this transition effectively, it could emerge leaner, more resilient and well-adapted to the evolving healthcare environment.
How Are Other Government Sponsored Health Plan Providers Placed?
Molina Healthcare (MOH - Free Report) , with nearly 88% Medicaid membership, faces major revenue challenges under OBBBA. Molina could be hit by tighter eligibility and shrinking enrollment. Still, Molina’s strong cost discipline and coordinated care model may support resilience amid the shifting healthcare policy environment.
UnitedHealth Group (UNH - Free Report) , with substantial Medicaid exposure, could also face revenue challenges due to OBBBA, given tighter eligibility and reduced enrollment. While UnitedHealth's diversified portfolio offers some protection, it must proactively respond to regulatory changes to safeguard its position in the government-sponsored healthcare market.
CNC’s Price Performance
Shares of CNC have lost 57.6% year to date, underperforming the industry.
Image Source: Zacks Investment Research
CNC’s Expensive Valuation
CNC trades at a forward 12-month price-to-earnings of 8.98, below the industry average of 11.96.
Image Source: Zacks Investment Research
Estimate Movements for CNC
The Zacks Consensus Estimate for CNC’s second-quarter and third-quarter 2025 EPS witnessed a southward revision over the past seven days. The consensus estimate for full-year 2025 and 2026 EPS also followed suit.
Image Source: Zacks Investment Research
The consensus estimate for CNC’s 2025 revenues indicates a year-over-year increase but the same for EPS suggests a decline. For 2026, the case is exactly the opposite.
CNC stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.